16.73

1.06% -0.18

After Hours: 16.73

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $16.73, with a volume of 263.40K. It is down -1.06% in the last 24 hours and up +4.43% over the past month. Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Previous Close:

$16.91

Open:

$16.98

24h Volume:

263.40K

Relative Volume:

0.44

Market Cap:

$861.85M

Revenue:

$107.46M

Net Income/Loss:

$105.90M

P/E Ratio:

8.2511

EPS:

2.0276

Net Cash Flow:

$238.50M

1W Performance:

-0.18%

1M Performance:

+4.43%

6M Performance:

+11.91%

1Y Performance:

+62.59%

1-Day Range:

$16.65

$17.17

1-Week Range:

$16.45

$17.17

52-Week Range:

$8.33

$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TBPH Theravance Biopharma Inc	16.73	871.12M	107.46M	105.90M	238.50M	2.0276
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Downgrade	Oppenheimer	Outperform → Perform
Mar-04-26	Downgrade	B. Riley Securities	Buy → Neutral
Dec-03-25	Initiated	Oppenheimer	Outperform
Sep-12-25	Initiated	B. Riley Securities	Buy
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-12-24	Initiated	BTIG Research	Buy
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

05:23 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire

Apr 30, 2026

Apr 28, 2026

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - FinancialContent

Apr 28, 2026

Theravance Biopharma (NASDAQ: TBPH) sets 2026 AGM votes on board, pay, auditor - Stock Titan

Apr 28, 2026

A Pivotal Quarter for Theravance Biopharma (TBPH): Milestone Cash Influx and a Transition to Pure Commercial Play - AlphaStreet

Apr 28, 2026

Apr 27, 2026

Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN

Apr 27, 2026

Apr 26, 2026

Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN

Apr 26, 2026

Apr 25, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 25, 2026

Apr 24, 2026

Laughing Water Capital Adds Theravance Biopharma to Portfolio in Q1 2026 - HarianBasis.co

Apr 24, 2026

Laughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH) - Insider Monkey

Apr 24, 2026

Laughing Water Capital’s New Position: Theravance Biopharma (TBPH) - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Theravance and Mylan settle patent dispute with Eugia Pharma - MSN

Apr 23, 2026

How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily

Apr 23, 2026

Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat

Apr 23, 2026

Apr 22, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Connect - ACCESS Newswire

Apr 22, 2026

Apr 21, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Reach Out - ACCESS Newswire

Apr 21, 2026

Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH) - Seeking Alpha

Apr 21, 2026

Apr 20, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 20, 2026

Theravance Biopharma (TBPH) Stock: What Investors Should Know (-0.75%) 2026-04-20Buy Signals - Xã Thanh Hà

Apr 20, 2026

Apr 19, 2026

B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14 - Insider Monkey

Apr 19, 2026